Ocugen, Inc. Announces U.S. FDA Lifts Clinical Hold on the Submission of Its Investigational New Drug Application for Its COVID-19 Vaccine Candidate COVAXIN™ (BBV152)
MALVERN, Pa., Feb. 18, 2022 (GLOBE NEWSWIRE) — Ocugen, Inc. (NASDAQ: OCGN), a clinical-stage biopharmaceutical…
Helport AI Opens Thailand Office
playX Receives the ‘Enterprise Award’ at the Asia Golden Star Awards in Tokyo
Zhibao Technology Announces Receipt of Nasdaq Deficiency Letter
Fairfax County and Penzance Officials Break Ground on Next-Generation Digital Infrastructure Project to Power the World’s Deep Tech Future